Greenwich LifeSciences (GLSI) announced its partnership with clinical sites in Italy. The company has partnered with “Gruppo Italiano Mammella” – GIM -, the largest academic cooperative breast cancer research group in Italy, including over 150 participating centers and approximately 500 investigators, with 28 clinical trials on-going today. Breast cancer is the leading cause of death from cancer in women in Italy with 15,455 deaths in 2022. Nine of the top enrolling institutions belonging to GIM have agreed to participate in its Phase III clinical trial, FLAMINGO-01.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GLSI:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
